Search

Your search keyword '"Diamant, Zuzana"' showing total 174 results
Start Over Author "Diamant, Zuzana" Search Limiters Full Text
174 results on '"Diamant, Zuzana"'

3. Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline

Author

Khatri, Sumita B, Iaccarino, Jonathan M, Barochia, Amisha, Soghier, Israa, Akuthota, Praveen, Brady, Anna, Covar, Ronina A, Debley, Jason S, Diamant, Zuzana, Fitzpatrick, Anne M, Kaminsky, David A, Kenyon, Nicholas J, Khurana, Sandhya, Lipworth, Brian J, McCarthy, Kevin, Peters, Michael, Que, Loretta G, Ross, Kristie R, Schneider-Futschik, Elena K, Sorkness, Christine A, and Hallstrand, Teal S

Subjects
Lung, Clinical Trials and Supportive Activities, Clinical Research, Asthma, 7.3 Management and decision making, Management of diseases and conditions, Respiratory, Adrenal Cortex Hormones, Anti-Asthmatic Agents, Humans, Nitric Oxide, Practice Guidelines as Topic, United States, nitric oxide, asthma, inhaled steroids, airway disease, type 2 inflammation, American Thoracic Society Assembly on Allergy, Immunology, and Inflammation, Medical and Health Sciences, Respiratory System
Abstract

Background: The fractional exhaled nitric oxide (FENO) test is a point-of-care test that is used in the assessment of asthma. Objective: To provide evidence-based clinical guidance on whether FENO testing is indicated to optimize asthma treatment in patients with asthma in whom treatment is being considered. Methods: An international, multidisciplinary panel of experts was convened to form a consensus document regarding a single question relevant to the use of FENO. The question was selected from three potential questions based on the greatest perceived impact on clinical practice and the unmet need for evidence-based answers related to this question. The panel performed systematic reviews of published randomized controlled trials between 2004 and 2019 and followed the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework to develop recommendations. All panel members evaluated and approved the recommendations. Main Results: After considering the overall low quality of the evidence, the panel made a conditional recommendation for FENO-based care. In patients with asthma in whom treatment is being considered, we suggest that FENO is beneficial and should be used in addition to usual care. This judgment is based on a balance of effects that probably favors the intervention; the moderate costs and availability of resources, which probably favors the intervention; and the perceived acceptability and feasibility of the intervention in daily practice. Conclusions: Clinicians should consider this recommendation to measure FENO in patients with asthma in whom treatment is being considered based on current best available evidence.

Published
2021

4. Digital tools in allergy and respiratory care

Author

Verhoeven, Elisabeth, Rouadi, Philip, Jaoude, Eliane Abou, Abouzakouk, Mohamed, Ansotegui, Ignacio, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Azar, Cecilio, Bahna, Sami, Cuervo-Pardo, Lyda, Diamant, Zuzana, Douagui, Habib, Maximiliano Gómez, R., Díaz, Sandra González, Han, Joseph K., Idriss, Samar, Irani, Carla, Karam, Marilyn, Klimek, Ludger, Nsouli, Talal, Scadding, Glenis, Senior, Brent, Smith, Pete, Yáñez, Anahí, Zaitoun, Fares, and Hellings, Peter W.

Published
2022
Full Text
View/download PDF

6. Recommendations for asthma monitoring in children:A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO

Author

Papadopoulos, Nikolaos G., Custovic, Adnan, Deschildre, Antoine, Gern, James E., Nieto Garcia, Antonio, Miligkos, Michael, Phipatanakul, Wanda, Wong, Gary, Xepapadaki, Paraskevi, Agache, Ioana, Arasi, Stefania, Awad El-Sayed, Zeinab, Bacharier, Leonard B., Bonini, Matteo, Braido, Fulvio, Caimmi, Davide, Castro-Rodriguez, Jose A., Chen, Zhimin, Clausen, Michael, Craig, Timothy, Diamant, Zuzana, Ducharme, Francine M., Ebisawa, Motohiro, Eigenmann, Philippe, Feleszko, Wojciech, Fierro, Vincezo, Fiocchi, Alessandro, Garcia-Marcos, Luis, Goh, Anne, Gómez, René Maximiliano, Gotua, Maia, Hamelmann, Eckard, Hedlin, Gunilla, Hossny, Elham M., Ispayeva, Zhanat, Jackson, Daniel J., Jartti, Tuomas, Jeseňák, Miloš, Kalayci, Omer, Kaplan, Alan, Konradsen, Jon R., Kuna, Piotr, Lau, Susanne, Le Souef, Peter, Lemanske, Robert F., Levin, Michael, Makela, Mika J., Mathioudakis, Alexander G., Mazulov, Oleksandr, Morais-Almeida, Mário, Murray, Clare, Nagaraju, Karthik, Novak, Zoltan, Pawankar, Ruby, Pijnenburg, Marielle W., Pite, Helena, Pitrez, Paulo M., Pohunek, Petr, Price, David, Priftanji, Alfred, Ramiconi, Valeria, Rivero Yeverino, Daniela, Roberts, Graham, Sheikh, Aziz, Shen, Kun Ling, Szepfalusi, Zsolt, Tsiligianni, Ioanna, Turkalj, Mirjana, Turner, Steve, Umanets, Tetiana, Valiulis, Arunas, Vijveberg, Susanne, Wang, Jiu Yao, Winders, Tonya, Yon, Dong Keon, Yusuf, Osman M., Zar, Heather J., Papadopoulos, Nikolaos G., Custovic, Adnan, Deschildre, Antoine, Gern, James E., Nieto Garcia, Antonio, Miligkos, Michael, Phipatanakul, Wanda, Wong, Gary, Xepapadaki, Paraskevi, Agache, Ioana, Arasi, Stefania, Awad El-Sayed, Zeinab, Bacharier, Leonard B., Bonini, Matteo, Braido, Fulvio, Caimmi, Davide, Castro-Rodriguez, Jose A., Chen, Zhimin, Clausen, Michael, Craig, Timothy, Diamant, Zuzana, Ducharme, Francine M., Ebisawa, Motohiro, Eigenmann, Philippe, Feleszko, Wojciech, Fierro, Vincezo, Fiocchi, Alessandro, Garcia-Marcos, Luis, Goh, Anne, Gómez, René Maximiliano, Gotua, Maia, Hamelmann, Eckard, Hedlin, Gunilla, Hossny, Elham M., Ispayeva, Zhanat, Jackson, Daniel J., Jartti, Tuomas, Jeseňák, Miloš, Kalayci, Omer, Kaplan, Alan, Konradsen, Jon R., Kuna, Piotr, Lau, Susanne, Le Souef, Peter, Lemanske, Robert F., Levin, Michael, Makela, Mika J., Mathioudakis, Alexander G., Mazulov, Oleksandr, Morais-Almeida, Mário, Murray, Clare, Nagaraju, Karthik, Novak, Zoltan, Pawankar, Ruby, Pijnenburg, Marielle W., Pite, Helena, Pitrez, Paulo M., Pohunek, Petr, Price, David, Priftanji, Alfred, Ramiconi, Valeria, Rivero Yeverino, Daniela, Roberts, Graham, Sheikh, Aziz, Shen, Kun Ling, Szepfalusi, Zsolt, Tsiligianni, Ioanna, Turkalj, Mirjana, Turner, Steve, Umanets, Tetiana, Valiulis, Arunas, Vijveberg, Susanne, Wang, Jiu Yao, Winders, Tonya, Yon, Dong Keon, Yusuf, Osman M., and Zar, Heather J.

Abstract

Monitoring is a major component of asthma management in children. Regular monitoring allows for diagnosis confirmation, treatment optimization, and natural history review. Numerous factors that may affect disease activity and patient well-being need to be monitored: response and adherence to treatment, disease control, disease progression, comorbidities, quality of life, medication side-effects, allergen and irritant exposures, diet and more. However, the prioritization of such factors and the selection of relevant assessment tools is an unmet need. Furthermore, rapidly developing technologies promise new opportunities for closer, or even “real-time,” monitoring between visits. Following an approach that included needs assessment, evidence appraisal, and Delphi consensus, the PeARL Think Tank, in collaboration with major international professional and patient organizations, has developed a set of 24 recommendations on pediatric asthma monitoring, to support healthcare professionals in decision-making and care pathway design. (Figure presented.).

Published
2024

7. Evaluating treatment response to mepolizumab in patients with severe CRSwNP*

Author

Hopkins, Claire, Han, Joseph K., Lund, Valerie J., Bachert, Claus, Fokkens, Wytske J., Diamant, Zuzana, Mullol, Joaquim, Sousa, Ana R., Smith, Steven G., Yang, Shibing, Mayer, Bhabita, Yancey, Steve W., Chan, Robert H., and Lee, Stella E.

Subjects
nasal polyps, biological products, mepolizumab, systemic corticosteroid use, disease-specific quality of life
Abstract

Background: The SYNAPSE study (NCT03085797) demonstrated that mepolizumab decreased nasal polyp (NP) size and nasal obstruction in patients with chronic rhinosinusitis with NP (CRSwNP). Methods: SYNAPSE, a randomized, double-blind study, included patients with recurrent, refractory, severe CRSwNP, eligible for repeated surgery despite receiving standard of care (SoC). Patients received 4-weekly mepolizumab 100 mg or placebo subcutaneously plus SoC for 52 weeks. This post hoc analysis further characterized treatment responses and association with patient characteristics. The proportion of patients meeting any and each of five response criteria indicating improvement in disease-specific quality of life, NP size, nasal obstruction, loss of smell, and overall symptoms at Weeks 24 and 52, were assessed in subgroups: 1) no surgery; 2) neither surgery nor systemic corticosteroids (SCS). Results: Of 407 patients in the intention-to-treat population, 381 and 343 patients had no sinus surgery by Weeks 24 and 52, respectively. More mepolizumab- versus placebo-treated patients without surgery by Weeks 24 and 52 met each response criteria. Of the mepolizumab-treated patients without surgery by Week 24, 109 (55%) responded across ≥ 3 criteria, increasing to 126 (67%) by Week 52. Similar response trends were seen for patients with neither surgery nor SCS by Weeks 24 and 52. At either timepoint, there were no major differences in baseline characteristics between mepolizumab-treated full- (5/5 categories) and non-responders (0/5 categories). Conclusions: Most patients who completed SYNAPSE required neither surgery nor SCS use and in addition achieved a progressive and sustained clinical response to mepolizumab underscoring the therapeutic benefits of mepolizumab in severe CRSwNP.

Published
2023

9. Functional imaging for assessing regional lung ventilation in preclinical and clinical research

Author

Karmali, Dipan, primary, Sowho, Mudiaga, additional, Bose, Sonali, additional, Pearce, Jackson, additional, Tejwani, Vickram, additional, Diamant, Zuzana, additional, Yarlagadda, Keerthi, additional, Ponce, Erick, additional, Eikelis, Nina, additional, Otvos, Tamas, additional, Khan, Akram, additional, Lester, Michael, additional, Fouras, Andreas, additional, Kirkness, Jason, additional, and Siddharthan, Trishul, additional

Published
2023
Full Text
View/download PDF

11. A EUFOREA comment on a lost comorbidity of asthma

Author

Conti, Diego M, Hellings, Peter W, Diamant, Zuzana, Bjermer, Leif, Jesenak, Milos, Backer, Vibeke, Fokkens, Wytske, Lau, Susanne, Van Staeyen, Elizabeth, and Scadding, Glenis K

Subjects
Chronic rhinosinusitis without nasal polyps, Allergic rhinitis, Asthma, Chronic rhinosinusitis with nasal polyps, Comorbidities
Abstract

"Epidemiology of comorbidities and their association with asthma control" (Tomisa, G., Horváth, A., Sánta, B. et al. Epidemiology of comorbidities and their association with asthma control. Allergy Asthma Clin Immunol 17, 95 (2021). https://doi.org/10.1186/s13223-021-00598-3 ) is an interesting paper reflecting data collection from more than 12,000 asthmatic patients in Hungary regarding their condition and associated comorbidities. We found it valuable that the paper provides an overview of asthma comorbidities not usually considered in similar reports. Nevertheless, we believe that chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP or CRSsNP) should have been listed due to its high incidence and prevalence, its association with asthma which is also endorsed in both GINA and EPOS, as well as in several peer-reviewed scientific papers, and to reflect the role of this comorbidity in poor control and a most severe presentation of asthma for the patient. Consequently, several targeted therapies (especially monoclonal antibodies) used for several years in severe forms of asthma are now indicated also for the effective treatment of nasal polyps. ispartof: ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY vol:19 issue:1 ispartof: location:England status: published

Published
2023

12. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma:An EAACI position paper

Author

Kappen, Jasper, Diamant, Zuzana, Agache, Ioana, Bonini, Matteo, Bousquet, Jean, Canonica, G. Walter, Durham, Stephen R., Guibas, George V., Hamelmann, Eckard, Jutel, Marek, Papadopoulos, Nikolaos G., Roberts, Graham, Shamji, Mohamed H., Zieglmayer, Petra, Gerth van Wijk, Roy, Pfaar, Oliver, Kappen, Jasper, Diamant, Zuzana, Agache, Ioana, Bonini, Matteo, Bousquet, Jean, Canonica, G. Walter, Durham, Stephen R., Guibas, George V., Hamelmann, Eckard, Jutel, Marek, Papadopoulos, Nikolaos G., Roberts, Graham, Shamji, Mohamed H., Zieglmayer, Petra, Gerth van Wijk, Roy, and Pfaar, Oliver

Abstract

Introduction: In allergic asthma patients, one of the more common phenotypes might benefit from allergen immunotherapy (AIT) as add-on intervention to pharmacological treatment. AIT is a treatment with disease-modifying modalities, the evidence for efficacy is based on controlled clinical trials following standardized endpoint measures. However, so far there is a lack of a consensus for asthma endpoints in AIT trials. The aim of a task force (TF) of the European Academy of Allergy and Clinical Immunology (EAACI) is evaluating several outcome measures for AIT in allergic asthma. Methods: The following domains of outcome measures in asthmatic patients have been evaluated for this position paper (PP): (i) exacerbation rate, (ii) lung function, (iii) ICS withdrawal, (iv) symptoms and rescue medication use, (v) questionnaires (PROMS), (vi) bronchial/nasal provocation, (vii) allergen exposure chambers (AEC) and (viii) biomarkers. Results: Exacerbation rate can be used as a reliable objective primary outcome; however, there is limited evidence due to different definitions of exacerbation. The time after ICS withdrawal to first exacerbation is considered a primary outcome measure. Besides, the advantages and disadvantages and clinical implications of further domains of asthma endpoints in AIT trials are elaborated in this PP. Conclusion: This EAACI-PP aims to highlight important aspects of current asthma measures by critically evaluating their applicability for controlled trials of AIT.

Published
2023

13. EUFOREA pocket guide on the diagnosis and management of asthma:An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients

Author

Diamant, Zuzana, Jesenak, Milos, Hanania, Nicola A., Heaney, Liam G., Djukanovic, Ratko, Ryan, Dermot, Quirce, Santiago, Backer, Vibeke, Gaga, Mina, Pavord, Ian, Antolín-Amérigo, Darío, Assaf, Sara, Bakakos, Petros, Bobcakova, Anna, Busse, William, Kappen, Jasper, Loukides, Stelios, van Maaren, Maurits, Panzner, Petr, Pite, Helena, Spanevello, Antonio, Stenberg, Henning, Striz, Ilja, Thio, Boony, Vasakova, Martina Koziar, Conti, Diego, Fokkens, Wytske, Lau, Susanne, Scadding, Glenis K., Van Staeyen, Elizabeth, Hellings, Peter W., Bjermer, Leif, Diamant, Zuzana, Jesenak, Milos, Hanania, Nicola A., Heaney, Liam G., Djukanovic, Ratko, Ryan, Dermot, Quirce, Santiago, Backer, Vibeke, Gaga, Mina, Pavord, Ian, Antolín-Amérigo, Darío, Assaf, Sara, Bakakos, Petros, Bobcakova, Anna, Busse, William, Kappen, Jasper, Loukides, Stelios, van Maaren, Maurits, Panzner, Petr, Pite, Helena, Spanevello, Antonio, Stenberg, Henning, Striz, Ilja, Thio, Boony, Vasakova, Martina Koziar, Conti, Diego, Fokkens, Wytske, Lau, Susanne, Scadding, Glenis K., Van Staeyen, Elizabeth, Hellings, Peter W., and Bjermer, Leif

Published
2023

14. Allergen immunotherapy for allergic asthma:The future seems bright

Author

Diamant, Zuzana, van Maaren, Maurits, Muraro, Antonella, Jesenak, Milos, Striz, Ilja, Diamant, Zuzana, van Maaren, Maurits, Muraro, Antonella, Jesenak, Milos, and Striz, Ilja

Abstract

Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.

Published
2023

15. Chronic Rhinosinusitis Outcome Registry (CHRINOSOR):Establishment of an International Outcome Registry Driven by mHealth Technology

Author

Seys, Sven F., Hellings, Peter W., Alobid, Isam, Backer, Vibeke, Bequignon, Emilie, von Buchwald, Christian, Cavaliere, Carlo, Coste, André, Deneyer, Lauren, Diamant, Zuzana, Eckl-Dorna, Julia, Fokkens, Wytske J., Gane, Simon, Gevaert, Philippe, Holbaek-Haase, Christiane, Holzmeister, Clemens, Hopkins, Claire, Hox, Valérie, Huart, Caroline, Jankowski, Roger, Jorissen, Mark, Kjeldsen, Anette, Knipps, Lisa, Lange, Bibi, van der Lans, Rik, Laulajainen-Hongisto, Anu, Larsen, Kenneth, Liu, David T., Lund, Valerie, Mariën, Gert, Masieri, Simonetta, Mortuaire, Geoffrey, Mullol, Joaquim, Reitsma, Sietze, Rombaux, Philippe, Schneider, Sven, Steinsvik, Andreas, Tomazic, Peter Valentin, Toppila-Salmi, Sanna K., Van Gerven, Laura, Van Zele, Thibaut, Virkkula, Paula, Wagenmann, Martin, Bachert, Claus, Seys, Sven F., Hellings, Peter W., Alobid, Isam, Backer, Vibeke, Bequignon, Emilie, von Buchwald, Christian, Cavaliere, Carlo, Coste, André, Deneyer, Lauren, Diamant, Zuzana, Eckl-Dorna, Julia, Fokkens, Wytske J., Gane, Simon, Gevaert, Philippe, Holbaek-Haase, Christiane, Holzmeister, Clemens, Hopkins, Claire, Hox, Valérie, Huart, Caroline, Jankowski, Roger, Jorissen, Mark, Kjeldsen, Anette, Knipps, Lisa, Lange, Bibi, van der Lans, Rik, Laulajainen-Hongisto, Anu, Larsen, Kenneth, Liu, David T., Lund, Valerie, Mariën, Gert, Masieri, Simonetta, Mortuaire, Geoffrey, Mullol, Joaquim, Reitsma, Sietze, Rombaux, Philippe, Schneider, Sven, Steinsvik, Andreas, Tomazic, Peter Valentin, Toppila-Salmi, Sanna K., Van Gerven, Laura, Van Zele, Thibaut, Virkkula, Paula, Wagenmann, Martin, and Bachert, Claus

Abstract

Background: Real-world evidence (RWE) is a valuable instrument to better understand the patient journey and effectiveness of therapies. RWE on the prevalence of uncontrolled chronic rhinosinusitis (CRS) and CRS natural course of disease across Europe is scarce. In addition, there is limited RWE that enables comparison of the effectiveness of marketed therapies including topical or systemic corticosteroids, sinus surgery, or biologics. Objective: To establish an international CHRonic rhINOSinusitis Outcome Registry (CHRINOSOR) based on real-world data collection enabled by mobile health technology. Methodology: A digital platform, Galenus Health, supporting patients and physicians in the management of chronic respiratory diseases, is used to collect data on patient profile, disease history, patient outcomes, and a set of relevant clinical outcomes. Adult patients with a diagnosis of CRS are eligible for inclusion. Results: A collaborative scientific network of 17 university ear-nose-throat (ENT) clinics from 10 European countries has been established with the aim to collect real-world data in a longitudinal and standardized manner. The Galenus Health digital platform is currently being implemented in these ENT clinics taking into account legal, privacy, and data security aspects. Up to 300 patients have already been included. Conclusions: CHRINOSOR is a collaborative effort that aims at improving our understanding of CRS, its comorbidities, and the effectiveness of its treatments. Ultimately, these insights will guide us as scientific community to develop future care pathways informed by RWE.

Published
2023

16. Additional file 1 of Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

Author

Fokkens, Wytske, Trigg, Andrew, Lee, Stella E., Chan, Robert H., Diamant, Zuzana, Hopkins, Claire, Howarth, Peter, Lund, Valerie, Mayer, Bhabita, Sousa, Ana R., Yancey, Steve, and Tabberer, Maggie

Abstract

Additional file 1. Supplementary methods and results.

Published
2023
Full Text
View/download PDF

17. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19

Author

Sokolowska, Milena, Rovati, G Enrico, Diamant, Zuzana, Untersmayr, Eva, Schwarze, Jürgen, Lukasik, Zuzanna, Sava, Florentina, Angelina, Alba, Palomares, Oscar, Akdis, Cezmi A, et al, University of Zurich, and Sokolowska, Milena

Subjects
2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, Immunology, 2723 Immunology and Allergy, Immunology and Allergy, 610 Medicine & health
Published
2022

18. Corrigendum on: White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA

Author

De Prins, Louise, primary, Raap, Ulrike, additional, Mueller, Tara, additional, Schmid-Grendelmeier, Peter, additional, Haase, Christiane H., additional, Backer, Vibeke, additional, Fokkens, Wytske, additional, Benoist, Linda B., additional, Prokopakis, Emmanuel, additional, Doulaptsi, Maria, additional, Hopkins, Claire, additional, Claeys, Nele, additional, Teeling, Thijs, additional, Cypers, Lindsay, additional, Cools, Leen, additional, Bjermer, Leif H., additional, Diamant, Zuzana, additional, Wahn, Ulrich, additional, Scadding, Glenis, additional, Bachert, Claus, additional, Walther, Peter, additional, Patel, Sunni R., additional, Van Staeyen, Elizabeth, additional, and Hellings, Peter, additional

Published
2022
Full Text
View/download PDF

20. White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA

Author

De Prins, Louise, primary, Raap, Ulrike, additional, Mueller, Tara, additional, Schmid-Grendelmeier, Peter, additional, Haase, Christiane H., additional, Backer, Vibeke, additional, Fokkens, Wytske, additional, Benoist, Linda B., additional, Prokopakis, Emmanuel, additional, Doulaptsi, Maria, additional, Hopkins, Claire, additional, Claeys, Nele, additional, Teeling, Thijs, additional, Cypers, Lindsay, additional, Cools, Leen, additional, Bjermer, Leif H., additional, Diamant, Zuzana, additional, Wahn, Ulrich, additional, Scadding, Glenis, additional, Bachert, Claus, additional, Walther, Peter, additional, Patel, Sunni R., additional, Van Staeyen, Elizabeth, additional, and Hellings, Peter, additional

Published
2022
Full Text
View/download PDF

21. A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2

Author

Consejo Superior de Investigaciones Científicas (España), Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Riggioni, Carmen [0000-0002-8745-0228], Comberiat, Pasquale [0000-0001-5209-9733], Giovannini, Mattia [0000-0001-9568-6882], Agache, Ioana [0000-0001-7994-364X], Akdis, Mubeccel [0000-0003-0554-9943], Alves-Correia, Magna [0000-0002-7676-5558], Antó, Josep M. [0000-0002-4736-8529], Azkur, Ahmet Kursat [0000-0002-5597-8917], Azkur, Dilek [0000-0002-4396-9087], Boccabella, Cristina [0000-0003-1942-8886], Breiteneder, Heimo [0000-0003-2022-8689], Carvalho, Daniela [0000-0002-0432-3339], Vecillas, Leticia de las [0000-0003-4969-5678], Diamant, Zuzana [0000-0003-0133-0100], Eguiluz-Gracia, Ibon [0000-0002-3774-931X], Eiwegger, Thomas [0000-0002-2914-7829], Fokkens, Wytske [0000-0003-4852-229X], Gao, Ya-dong [0000-0003-1251-7608], Nadeau, Kari C. [0000-0002-2146-2955], O'Mahony, Liam [0000-0003-4705-3583], Pfaar, Oliver [0000-0003-4374-9639], Sanak, Marek [0000-0001-7635-8103], Schwarze, Jürgen [0000-0002-6899-748X], Sokolowska, Milena [0000-0001-9710-6685], Torres Jaén, María José [0000-0001-5228-471X], Veen, Willem van de [0000-0001-9951-6688], Zelm, Menno C. van [0000-0003-4161-1919], Wang, De Yun [0000-0002-0909-2963], Zhang, Luo [0000-0002-0910-9884], Jiménez Saiz, Rodrigo [0000-0002-0606-3251], Akdis, Cezmi A. [0000-0001-8020-019X], Riggioni, Carmen, Comberiat, Pasquale, Giovannini, Mattia, Agache, Ioana, Akdis, Mubeccel, Alves-Correia, Magna, Antó, Josep M., Arcolaci, Alessandra, Azkur, Ahmet Kursat, Azkur, Dilek, Beken, Burcin, Boccabella, Cristina, Bousquet, Jean, Breiteneder, Heimo, Carvalho, Daniela, Vecillas, Leticia de las, Diamant, Zuzana, Eguiluz-Gracia, Ibon, Eiwegger, Thomas, Eyerich, Stephanie, Fokkens, Wytske, Gao, Ya-dong, Hannachi, Farah, Johnston, Sebastian L., Jutel, Marek, Karavelia, Aspasia, Klimek, Ludfger, Moya, Beatriz, Nadeau, Kari C., O'Hehir, Robin, O'Mahony, Liam, Pfaar, Oliver, Sanak, Marek, Schwarze, Jürgen, Sokolowska, Milena, Torres Jaén, María José, Veen, Willem van de, Zelm, Menno C. van, Wang, De Yun, Zhang, Luo, Jiménez Saiz, Rodrigo, Akdis, Cezmi A., Consejo Superior de Investigaciones Científicas (España), Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Riggioni, Carmen [0000-0002-8745-0228], Comberiat, Pasquale [0000-0001-5209-9733], Giovannini, Mattia [0000-0001-9568-6882], Agache, Ioana [0000-0001-7994-364X], Akdis, Mubeccel [0000-0003-0554-9943], Alves-Correia, Magna [0000-0002-7676-5558], Antó, Josep M. [0000-0002-4736-8529], Azkur, Ahmet Kursat [0000-0002-5597-8917], Azkur, Dilek [0000-0002-4396-9087], Boccabella, Cristina [0000-0003-1942-8886], Breiteneder, Heimo [0000-0003-2022-8689], Carvalho, Daniela [0000-0002-0432-3339], Vecillas, Leticia de las [0000-0003-4969-5678], Diamant, Zuzana [0000-0003-0133-0100], Eguiluz-Gracia, Ibon [0000-0002-3774-931X], Eiwegger, Thomas [0000-0002-2914-7829], Fokkens, Wytske [0000-0003-4852-229X], Gao, Ya-dong [0000-0003-1251-7608], Nadeau, Kari C. [0000-0002-2146-2955], O'Mahony, Liam [0000-0003-4705-3583], Pfaar, Oliver [0000-0003-4374-9639], Sanak, Marek [0000-0001-7635-8103], Schwarze, Jürgen [0000-0002-6899-748X], Sokolowska, Milena [0000-0001-9710-6685], Torres Jaén, María José [0000-0001-5228-471X], Veen, Willem van de [0000-0001-9951-6688], Zelm, Menno C. van [0000-0003-4161-1919], Wang, De Yun [0000-0002-0909-2963], Zhang, Luo [0000-0002-0910-9884], Jiménez Saiz, Rodrigo [0000-0002-0606-3251], Akdis, Cezmi A. [0000-0001-8020-019X], Riggioni, Carmen, Comberiat, Pasquale, Giovannini, Mattia, Agache, Ioana, Akdis, Mubeccel, Alves-Correia, Magna, Antó, Josep M., Arcolaci, Alessandra, Azkur, Ahmet Kursat, Azkur, Dilek, Beken, Burcin, Boccabella, Cristina, Bousquet, Jean, Breiteneder, Heimo, Carvalho, Daniela, Vecillas, Leticia de las, Diamant, Zuzana, Eguiluz-Gracia, Ibon, Eiwegger, Thomas, Eyerich, Stephanie, Fokkens, Wytske, Gao, Ya-dong, Hannachi, Farah, Johnston, Sebastian L., Jutel, Marek, Karavelia, Aspasia, Klimek, Ludfger, Moya, Beatriz, Nadeau, Kari C., O'Hehir, Robin, O'Mahony, Liam, Pfaar, Oliver, Sanak, Marek, Schwarze, Jürgen, Sokolowska, Milena, Torres Jaén, María José, Veen, Willem van de, Zelm, Menno C. van, Wang, De Yun, Zhang, Luo, Jiménez Saiz, Rodrigo, and Akdis, Cezmi A.

Abstract

In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID‐19). This disease, caused by the severe acute respiratory syndrome–related coronavirus 2 (SARS‐CoV‐2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID‐19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence‐based medical advice on SARS‐CoV‐2 and COVID‐19. Although the majority of the patients show a very mild, self‐limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID‐19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a “cytokine storm” leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID‐19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID‐19–related topics should be based on more coordinated high‐quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS‐CoV‐2, COVID‐19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID‐19 and allergic disease.

Published
2020

23. Allergen provocation tests in respiratory research:building on 50 years of experience

Author

Gauvreau, Gail M., Davis, Beth E., Scadding, Guy, Boulet, Louis Philippe, Bjermer, Leif, Chaker, Adam, Cockcroft, Donald W., Dahlén, Barbro, Fokkens, Wyste, Hellings, Peter, Lazarinis, Nikolaos, O'Byrne, Paul M., Tufvesson, Ellen, Quirce, Santiago, Van Maaren, Maurits, de Jongh, Frans H., Diamant, Zuzana, Gauvreau, Gail M., Davis, Beth E., Scadding, Guy, Boulet, Louis Philippe, Bjermer, Leif, Chaker, Adam, Cockcroft, Donald W., Dahlén, Barbro, Fokkens, Wyste, Hellings, Peter, Lazarinis, Nikolaos, O'Byrne, Paul M., Tufvesson, Ellen, Quirce, Santiago, Van Maaren, Maurits, de Jongh, Frans H., and Diamant, Zuzana

Abstract

The allergen provocation test is an established model of allergic airway diseases, including asthma and allergic rhinitis, allowing the study of allergen-induced changes in respiratory physiology and inflammatory mechanisms in sensitised individuals as well as their associations. In the upper airways, allergen challenge is focused on the clinical and pathophysiological sequelae of the early allergic response, and is applied both as a diagnostic tool and in research settings. In contrast, bronchial allergen challenge has almost exclusively served as a research tool in specialised research settings with a focus on the late asthmatic response and the underlying type 2 inflammation. The allergen-induced late asthmatic response is also characterised by prolonged airway narrowing, increased nonspecific airway hyperresponsiveness and features of airway remodelling including the small airways, and hence allows the study of several key mechanisms and features of asthma. In line with these characteristics, allergen challenge has served as a valued tool to study the cross-talk of the upper and lower airways and in proof-of-mechanism studies of drug development. In recent years, several new insights into respiratory phenotypes and endotypes including the involvement of the upper and small airways, innovative biomarker sampling methods and detection techniques, refined lung function testing as well as targeted treatment options further shaped the applicability of the allergen provocation test in precision medicine. These topics, along with descriptions of subject populations and safety, in line with the updated Global Initiative for Asthma 2021 document, will be addressed in this review.

Published
2022

24. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19

Author

Sokolowska, Milena; https://orcid.org/0000-0001-9710-6685, Rovati, G Enrico; https://orcid.org/0000-0002-8788-9783, Diamant, Zuzana; https://orcid.org/0000-0003-0133-0100, Untersmayr, Eva; https://orcid.org/0000-0002-1963-499X, Schwarze, Jürgen, Lukasik, Zuzanna, Sava, Florentina; https://orcid.org/0000-0001-8936-3542, Angelina, Alba, Palomares, Oscar; https://orcid.org/0000-0003-4516-0369, Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X, et al, Sokolowska, Milena; https://orcid.org/0000-0001-9710-6685, Rovati, G Enrico; https://orcid.org/0000-0002-8788-9783, Diamant, Zuzana; https://orcid.org/0000-0003-0133-0100, Untersmayr, Eva; https://orcid.org/0000-0002-1963-499X, Schwarze, Jürgen, Lukasik, Zuzanna, Sava, Florentina; https://orcid.org/0000-0001-8936-3542, Angelina, Alba, Palomares, Oscar; https://orcid.org/0000-0003-4516-0369, Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X, and et al

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti-inflammatory, antipyretic, and analgesic effects are applied against symptoms of respiratory infections, including SARS-CoV-2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs-exacerbated respiratory disease (NERD). In this context, the consensus report summarizes currently available knowledge, novel discoveries, and controversies regarding the use of NSAIDs in COVID-19, and the role of NSAIDs in asthma and viral asthma exacerbations. We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID-19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarize the major knowledge gaps and unmet needs in current eicosanoid research.

Published
2022

25. White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA

Author

De Prins, Louise, Raap, Ulrike, Mueller, Tara, Schmid-Grendelmeier, Peter, Haase, Christiane H, Backer, Vibeke, Fokkens, Wytske, Benoist, Linda B, Prokopakis, Emmanuel, Doulaptsi, Maria, Hopkins, Claire, Claeys, Nele, Teeling, Thijs, Cypers, Lindsay, Cools, Leen, Bjermer, Leif H, Diamant, Zuzana, Wahn, Ulrich, Scadding, Glenis, Bachert, Claus, Walther, Peter, Patel, Sunni R, Van Staeyen, Elizabeth, Hellings, Peter, De Prins, Louise, Raap, Ulrike, Mueller, Tara, Schmid-Grendelmeier, Peter, Haase, Christiane H, Backer, Vibeke, Fokkens, Wytske, Benoist, Linda B, Prokopakis, Emmanuel, Doulaptsi, Maria, Hopkins, Claire, Claeys, Nele, Teeling, Thijs, Cypers, Lindsay, Cools, Leen, Bjermer, Leif H, Diamant, Zuzana, Wahn, Ulrich, Scadding, Glenis, Bachert, Claus, Walther, Peter, Patel, Sunni R, Van Staeyen, Elizabeth, and Hellings, Peter

Abstract

Background: Type 2 inflammation underlies the chronicity of disease in subgroups of patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD), that often co-exist. Although several studies have investigated the unmet needs of asthma, AD and CRSwNP as such, little is known about the similarities and differences in experiences and perspectives of the current management of patients with comorbid Type 2 inflammatory diseases. Aims: To improve insight into the common and organ-specific needs of patients with Type 2 inflammation and comorbidities, allowing the formulation of recommendations to better address these needs in the future. Methodology: This qualitative study was conducted between July 2021 and December 2021 using semi-structured face-to-face or telephone interviews with patients suffering from year-long severe chronic Type 2 inflammation and at least one co-morbid inflammatory condition. Seven participating academic centers in Europe interviewed asthma (Copenhagen and Leuven), CRSwNP (London, Amsterdam and Crete) and/or AD (Oldenburg and Zurich) patients on patient characteristics, disease severity, shortcomings of current care pathways and suggestions for improvement of care. Transcripts were analyzed using an inductive thematic analysis approach. Results: Eighty-one patients with severe Type 2 inflammation and comorbidities were interviewed. Similar needs were recognized by patients with Type 2 inflammation, with both a lack of coordination in care and a lack of a real cure reported as being most frustrating. However, several needs are specific to asthma, CRSwNP and AD. Suggestions for improvement of care were generic across diseases, such as the implementation of a multidisciplinary approach, the improved facilitation of access to better treatments, the increase of general awareness on disease burden, and better educational programs for healthcare providers and patients. Of note, patients with CRSwNP also stated the

Published
2022

26. Corrigendum on: White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA

Author

De Prins, Louise, Raap, Ulrike, Mueller, Tara, Schmid-Grendelmeier, Peter, Haase, Christiane H, Backer, Vibeke, Fokkens, Wytske, Benoist, Linda B, Prokopakis, Emmanuel, Doulaptsi, Maria, Hopkins, Claire, Claeys, Nele, Teeling, Thijs, Cypers, Lindsay, Cools, Leen, Bjermer, Leif H, Diamant, Zuzana, Wahn, Ulrich, Scadding, Glenis, Bachert, Claus, Walther, Peter, Patel, Sunni R, Van Staeyen, Elizabeth, Hellings, Peter, De Prins, Louise, Raap, Ulrike, Mueller, Tara, Schmid-Grendelmeier, Peter, Haase, Christiane H, Backer, Vibeke, Fokkens, Wytske, Benoist, Linda B, Prokopakis, Emmanuel, Doulaptsi, Maria, Hopkins, Claire, Claeys, Nele, Teeling, Thijs, Cypers, Lindsay, Cools, Leen, Bjermer, Leif H, Diamant, Zuzana, Wahn, Ulrich, Scadding, Glenis, Bachert, Claus, Walther, Peter, Patel, Sunni R, Van Staeyen, Elizabeth, and Hellings, Peter

Abstract

Background: Type 2 inflammation underlies the chronicity of disease in subgroups of patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD), that often co-exist. Although several studies have investigated the unmet needs of asthma, AD and CRSwNP as such, little is known about the similarities and differences in experiences and perspectives of the current management of patients with comorbid Type 2 inflammatory diseases. Aims: To improve insight into the common and organ-specific needs of patients with Type 2 inflammation and comorbidities, allowing the formulation of recommendations to better address these needs in the future. Methodology: This qualitative study was conducted between July 2021 and December 2021 using semi-structured face-to-face or telephone interviews with patients suffering from year-long severe chronic Type 2 inflammation and at least one co-morbid inflammatory condition. Seven participating academic centers in Europe interviewed asthma (Copenhagen and Leuven), CRSwNP (London, Amsterdam and Crete) and/or AD (Oldenburg and Zurich) patients on patient characteristics, disease severity, shortcomings of current care pathways and suggestions for improvement of care. Transcripts were analyzed using an inductive thematic analysis approach. Results: Eighty-one patients with severe Type 2 inflammation and comorbidities were interviewed. Similar needs were recognized by patients with Type 2 inflammation, with both a lack of coordination in care and a lack of a real cure reported as being most frustrating. However, several needs are specific to asthma, CRSwNP and AD. Suggestions for improvement of care were generic across diseases, such as the implementation of a multidisciplinary approach, the improved facilitation of access to better treatments, the increase of general awareness on disease burden, and better educational programs for healthcare providers and patients. Of note, patients with CRSwNP also stated the

Published
2022

30. Allergen provocation tests in respiratory research: building on 50 years of experience

Author

Gauvreau, Gail M., primary, Davis, Beth E., additional, Scadding, Guy, additional, Boulet, Louis-Philippe, additional, Bjermer, Leif, additional, Chaker, Adam, additional, Cockcroft, Donald W., additional, Dahlén, Barbro, additional, Fokkens, Wyste, additional, Hellings, Peter, additional, Lazarinis, Nikolaos, additional, O'Byrne, Paul M., additional, Tufvesson, Ellen, additional, Quirce, Santiago, additional, Van Maaren, Maurits, additional, de Jongh, Frans H., additional, and Diamant, Zuzana, additional

Published
2022
Full Text
View/download PDF

31. Study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank

Author

Mathioudakis, Alexander G., Miligkos, Michael, Boccabella, Cristina, Alimani, Gioulinta S., Custovic, Adnan, Deschildre, A., Ducharme, Francine Monique, Kalayci, Omer, Murray, Clare, Garcia, Antonio Nieto, Phipatanakul, Wanda, Price, David, Sheikh, Aziz, Agache, Ioana Octavia, Bacharier, Leonard, Beloukas, Apostolos, Bentley, Andrew, Bonini, Matteo, Castro-Rodriguez, Jose A., De Carlo, Giuseppe, Craig, Timothy, Diamant, Zuzana, Feleszko, Wojciech, Felton, Tim, Gern, James E., Grigg, Jonathan, Hedlin, Gunilla, Hossny, Elham M., Ierodiakonou, Despo, Jartti, Tuomas, Kaplan, Alan, Lemanske, Robert F., Le Souëf, Peter N., Mäkelä, Mika J., Mathioudakis, Georgios A., Matricardi, Paolo, Mitrogiorgou, Marina, Morais-Almeida, Mario, Nagaraju, Karthik, Papageorgiou, Effie, Pité, Helena, Pitrez, Paulo M.C., Pohunek, Petr, Roberts, Graham, Tsiligianni, Ioanna, Turner, Stephen, Vijverberg, Susanne, Winders, Tonya A., Wong, Gary W.K., Xepapadaki, Paraskevi, Zar, Heather J., Papadopoulos, Nikolaos G., Centro de Estudos de Doenças Crónicas (CEDOC), and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Subjects
paediatrics, Medicine(all), thoracic medicine, education, paediatric thoracic medicine, asthma
Abstract

Funding Information: AGM was supported by the National Institute of Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC). We thank Mrs Maria Kritikou for excellent administrative support of the study Publisher Copyright: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. Copyright: Copyright 2021 Elsevier B.V., All rights reserved. Introduction Clinical recommendations for childhood asthma are often based on data extrapolated from studies conducted in adults, despite significant differences in mechanisms and response to treatments. The Paediatric Asthma in Real Life (PeARL) Think Tank aspires to develop recommendations based on the best available evidence from studies in children. An overview of systematic reviews (SRs) on paediatric asthma maintenance management and an SR of treatments for acute asthma attacks in children, requiring an emergency presentation with/without hospital admission will be conducted. Methods and analysis Standard methodology recommended by Cochrane will be followed. Maintenance pharmacotherapy of childhood asthma will be evaluated in an overview of SRs published after 2005 and including clinical trials or real-life studies. For evaluating pharmacotherapy of acute asthma attacks leading to an emergency presentation with/without hospital admission, we opted to conduct de novo synthesis in the absence of adequate up-to-date published SRs. For the SR of acute asthma pharmacotherapy, we will consider eligible SRs, clinical trials or real-life studies without time restrictions. Our evidence updates will be based on broad searches of Pubmed/Medline and the Cochrane Library. We will use A MeaSurement Tool to Assess systematic Reviews, V.2, Cochrane risk of bias 2 and REal Life EVidence AssessmeNt Tool to evaluate the methodological quality of SRs, controlled clinical trials and real-life studies, respectively. Next, we will further assess interventions for acute severe asthma attacks with positive clinical results in meta-analyses. We will include both controlled clinical trials and observational studies and will assess their quality using the previously mentioned tools. We will employ random effect models for conducting meta-analyses, and Grading of Recommendations Assessment, Development and Evaluation methodology to assess certainty in the body of evidence. Ethics and dissemination Ethics approval is not required for SRs. Our findings will be published in peer reviewed journals and will inform clinical recommendations being developed by the PeARL Think Tank. PROSPERO registration numbers CRD42020132990, CRD42020171624. publishersversion published

Published
2021

32. Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank

Author

Mathioudakis, Alexander G, primary, Miligkos, Michael, additional, Boccabella, Cristina, additional, Alimani, Gioulinta S, additional, Custovic, Adnan, additional, Deschildre, A, additional, Ducharme, Francine Monique, additional, Kalayci, Omer, additional, Murray, Clare, additional, Garcia, Antonio Nieto, additional, Phipatanakul, Wanda, additional, Price, David, additional, Sheikh, Aziz, additional, Agache, Ioana Octavia, additional, Bacharier, Leonard, additional, Beloukas, Apostolos, additional, Bentley, Andrew, additional, Bonini, Matteo, additional, Castro-Rodriguez, Jose A, additional, De Carlo, Giuseppe, additional, Craig, Timothy, additional, Diamant, Zuzana, additional, Feleszko, Wojciech, additional, Felton, Tim, additional, Gern, James E, additional, Grigg, Jonathan, additional, Hedlin, Gunilla, additional, Hossny, Elham M, additional, Ierodiakonou, Despo, additional, Jartti, Tuomas, additional, Kaplan, Alan, additional, Lemanske, Robert F, additional, Le Souëf, Peter N, additional, Mäkelä, Mika J, additional, Mathioudakis, Georgios A, additional, Matricardi, Paolo, additional, Mitrogiorgou, Marina, additional, Morais-Almeida, Mario, additional, Nagaraju, Karthik, additional, Papageorgiou, Effie, additional, Pité, Helena, additional, Pitrez, Paulo M C, additional, Pohunek, Petr, additional, Roberts, Graham, additional, Tsiligianni, Ioanna, additional, Turner, Stephen, additional, Vijverberg, Susanne, additional, Winders, Tonya A, additional, Wong, Gary WK, additional, Xepapadaki, Paraskevi, additional, Zar, Heather J, additional, and Papadopoulos, Nikolaos G, additional

Published
2021
Full Text
View/download PDF

33. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort

Author

Papadopoulos, Nikolaos G., Mathioudakis, Alexander G., Custovic, Adnan, Deschildre, Antoine, Phipatanakul, Wanda, Wong, Gary, Xepapadaki, Paraskevi, Abou‐taam, Rola, Agache, Ioana, Castro‐rodriguez, Jose A., Chen, Zhimin, Cros, Pierrick, Dubus, Jean‐christophe, El‐sayed, Zeinab Awad, El‐owaidy, Rasha, Feleszko, Wojciech, Fierro, Vincenzo, Fiocchi, Alessandro, Garcia‐marcos, Luis, Goh, Anne, Hossny, Elham M., Huerta Villalobos, Yunuen R., Jartti, Tuomas, Le Roux, Pascal, Levina, Julia, López García, Aida Inés, Ramos, Ángel Mazón, Morais‐almeida, Mário, Murray, Clare, Nagaraju, Karthik, Nagaraju, Major K., Navarrete Rodriguez, Elsy Maureen, Namazova‐baranova, Leyla, Nieto Garcia, Antonio, Pozo Beltrán, Cesar Fireth, Ratchataswan, Thanaporn, Rivero Yeverino, Daniela, Rodríguez Zagal, Eréndira, Schweitzer, Cyril E., Tulkki, Marleena, Wasilczuk, Katarzyna, Xu, Dan, Alekseeva, Anna, Almeida, Bethan, Andre, Maud, Arimova, Polina, Blonde, Aurore, Cunningham, Amparito, Da Mota, Sofia, Efendieva, Kamilla, Kalugina, Vera, Kiefer, Sébastien, Klein, Anais, López, Chrystopherson Gengyny Caballero, López, Juan Jesús Ríos, Moratellti, Caroline, Fuentes Pérez, Miguel, Simermann, Meryl, Tapia, José Sergio Papaqui, Tatopoulos, Aurelie, Vishneva, Elena, Volkov, Κonstantin, Bacharier, Leonard, Bonini, Matteo, Craig, Timothy, Diamant, Zuzana, Ducharme, Francine M, Gern, James E., Grigg, Jonathan, Hamelmann, Eckard H, Hedlin, Gunilla, Kalayci, Omer, Kaplan, Alan, Konradsen, Jon, Kuna, Piotr, Lau, Susanne, Le Souef, Peter, Lemanske, Robert F, Makela, Mika J, Matricardi, Paolo M, Gómez, René‐maximiliano, Miligkos, Michael, Pitrez, Paulo Mc, Price, David, Pohunek, Petr, Roberts, Graham C, Sheikh, Aziz, Tsiligianni, Ioanna, Turner, Steve, Valiulis, Arunas, Winders, Tonya, Yusuf, Osman M, Zar, Heather, University of Manchester [Manchester], Pneumologie et allergologie pédiatriques [CHU Jeanne de Flandre, Lille], Hôpital Jeanne de Flandre [Lille], Université de Lille, The Chinese University of Hong Kong [Hong Kong], Department of Nutrition and Dietetics [Athens, Greece], Harokopio University [Athens, Greece], Transilvania University of Brasov, CHRU de Brest - Département de Pédiatrie (CHU BREST Pédiatrie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de pédiatrie spécialisée et médecine infantile (neurologie, pneumologie, maladies héréditaires du métabolisme) [Hôpital de la Timone - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE), Medical University of Warsaw - Poland, and Bambino Gesù Children’s Hospital [Rome, Italy]

Subjects
0301 basic medicine, Pediatrics, Allergy, coronavirus, CHILDREN, Pulmonary function testing, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, immune system diseases, childhood asthma, Pandemic, Immunology and Allergy, Medicine, Outpatient clinic, Child, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Respiratory tract infections, Minimal clinically important difference, PeARL collaborators, on behalf of the PeARL Think Tank, Hospitalization, 1107 Immunology, Child, Preschool, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Cohort, Original Article, PEDIATRIC ASTHMA, COVID-19, Life Sciences & Biomedicine, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Adolescent, Immunology, VALIDATION, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, COVID‐19, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Risk factor, Pandemics, Asthma, Childhood asthma, Science & Technology, SARS-CoV-2, business.industry, Original Articles, medicine.disease, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, respiratory tract diseases, EXACERBATIONS, 030104 developmental biology, 030228 respiratory system, Emergency medicine, business, ACUTE RESPIRATORY SYNDROME
Abstract

Background The interplay between COVID‐19 pandemic and asthma in children is still unclear. We evaluated the impact of COVID‐19 pandemic on childhood asthma outcomes. Methods The PeARL multinational cohort included 1,054 children with asthma and 505 non‐asthmatic children aged between 4 and 18 years from 25 pediatric departments, from 15 countries globally. We compared the frequency of acute respiratory and febrile presentations during the first wave of the COVID‐19 pandemic between groups and with data available from the previous year. In children with asthma, we also compared current and historical disease control. Results During the pandemic, children with asthma experienced fewer upper respiratory tract infections, episodes of pyrexia, emergency visits, hospital admissions, asthma attacks, and hospitalizations due to asthma, in comparison with the preceding year. Sixty‐six percent of asthmatic children had improved asthma control while in 33% the improvement exceeded the minimal clinically important difference. Pre‐bronchodilatation FEV1 and peak expiratory flow rate were improved during the pandemic. When compared to non‐asthmatic controls, children with asthma were not at increased risk of LRTIs, episodes of pyrexia, emergency visits, or hospitalizations during the pandemic. However, an increased risk of URTIs emerged. Conclusion Childhood asthma outcomes, including control, were improved during the first wave of the COVID‐19 pandemic, probably because of reduced exposure to asthma triggers and increased treatment adherence. The decreased frequency of acute episodes does not support the notion that childhood asthma may be a risk factor for COVID‐19. Furthermore, the potential for improving childhood asthma outcomes through environmental control becomes apparent., This study evaluates the frequency of acute respiratory and febrile presentations furing the first wave of COVID‐19 pandemic in childhood asthma. Data from the multinational PeARL cohort reveal improved health and asthma activity during the first wave of the COVID‐19 pandemic, probably attributed to decreased exposure to asthma triggers and increased treatment adherence. During that period, children with asthma experienced fewer URTIs, episodes of pyrexia, emergency visits, hospital admissions, asthma attacks and hospitalizations due to asthma, in comparison to the preceding year.

Published
2021

34. Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank

Author

Mathioudakis, Alexander G. Miligkos, Michael Boccabella, Cristina Alimani, Gioulinta S. Custovic, Adnan Deschildre, A. Ducharme, Francine Monique Kalayci, Omer Murray, Clare and Garcia, Antonio Nieto Phipatanakul, Wanda Price, David and Sheikh, Aziz Agache, Ioana Octavia Bacharier, Leonard and Beloukas, Apostolos Bentley, Andrew Bonini, Matteo and Castro-Rodriguez, Jose A. De Carlo, Giuseppe Craig, Timothy and Diamant, Zuzana Feleszko, Wojciech Felton, Tim Gern, James E. Grigg, Jonathan Hedlin, Gunilla Hossny, Elham M. and Ierodiakonou, Despo Jartti, Tuomas Kaplan, Alan Lemanske, Robert F. Le Souef, Peter N. Makela, Mika J. Mathioudakis, Georgios A. Matricardi, Paolo Mitrogiorgou, Marina and Morais-Almeida, Mario Nagaraju, Karthik Papageorgiou, Effie and Pite, Helena Pitrez, Paulo M. C. Pohunek, Petr Roberts, Graham Tsiligianni, Ioanna Turner, Stephen Vijverberg, Susanne Winders, Tonya A. Wong, Gary W. K. Xepapadaki, Paraskevi Zar, Heather J. Papadopoulos, Nikolaos G.

Abstract

Introduction Clinical recommendations for childhood asthma are often based on data extrapolated from studies conducted in adults, despite significant differences in mechanisms and response to treatments. The Paediatric Asthma in Real Life (PeARL) Think Tank aspires to develop recommendations based on the best available evidence from studies in children. An overview of systematic reviews (SRs) on paediatric asthma maintenance management and an SR of treatments for acute asthma attacks in children, requiring an emergency presentation with/without hospital admission will be conducted. Methods and analysis Standard methodology recommended by Cochrane will be followed. Maintenance pharmacotherapy of childhood asthma will be evaluated in an overview of SRs published after 2005 and including clinical trials or real-life studies. For evaluating pharmacotherapy of acute asthma attacks leading to an emergency presentation with/without hospital admission, we opted to conduct de novo synthesis in the absence of adequate up-to-date published SRs. For the SR of acute asthma pharmacotherapy, we will consider eligible SRs, clinical trials or real-life studies without time restrictions. Our evidence updates will be based on broad searches of Pubmed/Medline and the Cochrane Library. We will use A MeaSurement Tool to Assess systematic Reviews, V.2, Cochrane risk of bias 2 and REal Life EVidence AssessmeNt Tool to evaluate the methodological quality of SRs, controlled clinical trials and real-life studies, respectively. Next, we will further assess interventions for acute severe asthma attacks with positive clinical results in meta-analyses. We will include both controlled clinical trials and observational studies and will assess their quality using the previously mentioned tools. We will employ random effect models for conducting meta-analyses, and Grading of Recommendations Assessment, Development and Evaluation methodology to assess certainty in the body of evidence. Ethics and dissemination Ethics approval is not required for SRs. Our findings will be published in peer reviewed journals and will inform clinical recommendations being developed by the PeARL Think Tank. PROSPERO registration numbers CRD42020132990, CRD42020171624.

Published
2021

35. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper.

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'oto-rhino-laryngologie, Pfaar, Oliver, Klimek, Ludger, Jutel, Marek, Akdis, Cezmi A, Bousquet, Jean, Breiteneder, Heimo, Chinthrajah, Sharon, Diamant, Zuzana, Eiwegger, Thomas, Fokkens, Wytske J, Fritsch, Hans-Walter, Nadeau, Kari C, O'Hehir, Robyn E, O'Mahony, Liam, Rief, Winfried, Sampath, Vanitha, Schedlowski, Manfred, Torres, María José, Traidl-Hoffmann, Claudia, Wang, De Yun, Zhang, Luo, Bonini, Matteo, Brehler, Randolf, Brough, Helen Annaruth, Chivato, Tomás, Del Giacco, Stefano R, Dramburg, Stephanie, Gawlik, Radoslaw, Gelincik, Aslı, Hoffmann-Sommergruber, Karin, Hox, Valérie, Knol, Edward F, Lauerma, Antti, Matricardi, Paolo M, Mortz, Charlotte G, Ollert, Markus, Palomares, Oscar, Riggioni, Carmen, Schwarze, Jürgen, Skypala, Isabel, Untersmayr, Eva, Walusiak-Skorupa, Jolanta, Ansotegui, Ignacio J, Bachert, Claus, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, Giorgio Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Cruz, Alvaro A, Czarlewski, Wienczyslawa, Fonseca, João A, Gotua, Maia, Haahtela, Tari, Ivancevich, Juan Carlos, Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Désirée Erlinda, Abdul Latiff, Amir Hamzah, Mäkelä, Mika, Morais-Almeida, Mário, Mullol, Joaquim, Naclerio, Robert, Ohta, Ken, Okamoto, Yoshitaka, Onorato, Gabrielle L, Papadopoulos, Nikolaos G, Patella, Vincenzo, Regateiro, Frederico S, Samoliński, Bolesław, Suppli Ulrik, Charlotte, Toppila-Salmi, Sanna, Valiulis, Arunas, Ventura, Maria-Teresa, Yorgancioglu, Arzu, Zuberbier, Torsten, Agache, Ioana, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'oto-rhino-laryngologie, Pfaar, Oliver, Klimek, Ludger, Jutel, Marek, Akdis, Cezmi A, Bousquet, Jean, Breiteneder, Heimo, Chinthrajah, Sharon, Diamant, Zuzana, Eiwegger, Thomas, Fokkens, Wytske J, Fritsch, Hans-Walter, Nadeau, Kari C, O'Hehir, Robyn E, O'Mahony, Liam, Rief, Winfried, Sampath, Vanitha, Schedlowski, Manfred, Torres, María José, Traidl-Hoffmann, Claudia, Wang, De Yun, Zhang, Luo, Bonini, Matteo, Brehler, Randolf, Brough, Helen Annaruth, Chivato, Tomás, Del Giacco, Stefano R, Dramburg, Stephanie, Gawlik, Radoslaw, Gelincik, Aslı, Hoffmann-Sommergruber, Karin, Hox, Valérie, Knol, Edward F, Lauerma, Antti, Matricardi, Paolo M, Mortz, Charlotte G, Ollert, Markus, Palomares, Oscar, Riggioni, Carmen, Schwarze, Jürgen, Skypala, Isabel, Untersmayr, Eva, Walusiak-Skorupa, Jolanta, Ansotegui, Ignacio J, Bachert, Claus, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, Giorgio Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Cruz, Alvaro A, Czarlewski, Wienczyslawa, Fonseca, João A, Gotua, Maia, Haahtela, Tari, Ivancevich, Juan Carlos, Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Désirée Erlinda, Abdul Latiff, Amir Hamzah, Mäkelä, Mika, Morais-Almeida, Mário, Mullol, Joaquim, Naclerio, Robert, Ohta, Ken, Okamoto, Yoshitaka, Onorato, Gabrielle L, Papadopoulos, Nikolaos G, Patella, Vincenzo, Regateiro, Frederico S, Samoliński, Bolesław, Suppli Ulrik, Charlotte, Toppila-Salmi, Sanna, Valiulis, Arunas, Ventura, Maria-Teresa, Yorgancioglu, Arzu, Zuberbier, Torsten, and Agache, Ioana

Abstract

BACKGROUND: The coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics. METHOD: The scientific information on COVID-19 was analysed by a literature search in MEDLINE, PubMed, the National and International Guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library, and the internet. RESULTS: Based on the diagnostic and treatment standards developed by EAACI, on international information regarding COVID-19, on guidelines of the World Health Organization (WHO) and other international organizations, and on previous experience, a panel of experts including clinicians, psychologists, IT experts, and basic scientists along with EAACI and the "Allergic Rhinitis and its Impact on Asthma (ARIA)" initiative have developed recommendations for the optimal management of allergy clinics during the current COVID-19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies. CONCLUSIONS: This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID-19 pandemic.

Published
2021

36. Vaccines and allergic reactions:The past, the current COVID-19 pandemic, and future perspectives

Author

Sampath, Vanitha, Rabinowitz, Grace, Shah, Mihir, Jain, Surabhi, Diamant, Zuzana, Jesenak, Milos, Rabin, Ronald, Vieths, Stefan, Agache, Ioana, Akdis, Mübeccel, Barber, Domingo, Breiteneder, Heimo, Chinthrajah, Sharon, Chivato, Tomas, Collins, William, Eiwegger, Thomas, Fast, Katharine, Fokkens, Wytske, O'Hehir, Robyn E., Ollert, Markus, O'Mahony, Liam, Palomares, Oscar, Pfaar, Oliver, Riggioni, Carmen, Shamji, Mohamed H., Sokolowska, Milena, Jose Torres, Maria, Traidl-Hoffmann, Claudia, van Zelm, Menno, Wang, De Yun, Zhang, Luo, Akdis, Cezmi A., Nadeau, Kari C., Sampath, Vanitha, Rabinowitz, Grace, Shah, Mihir, Jain, Surabhi, Diamant, Zuzana, Jesenak, Milos, Rabin, Ronald, Vieths, Stefan, Agache, Ioana, Akdis, Mübeccel, Barber, Domingo, Breiteneder, Heimo, Chinthrajah, Sharon, Chivato, Tomas, Collins, William, Eiwegger, Thomas, Fast, Katharine, Fokkens, Wytske, O'Hehir, Robyn E., Ollert, Markus, O'Mahony, Liam, Palomares, Oscar, Pfaar, Oliver, Riggioni, Carmen, Shamji, Mohamed H., Sokolowska, Milena, Jose Torres, Maria, Traidl-Hoffmann, Claudia, van Zelm, Menno, Wang, De Yun, Zhang, Luo, Akdis, Cezmi A., and Nadeau, Kari C.

Abstract

Vaccines are essential public health tools with a favorable safety profile and prophylactic effectiveness that have historically played significant roles in reducing infectious disease burden in populations, when the majority of individuals are vaccinated. The COVID-19 vaccines are expected to have similar positive impacts on health across the globe. While serious allergic reactions to vaccines are rare, their underlying mechanisms and implications for clinical management should be considered to provide individuals with the safest care possible. In this review, we provide an overview of different types of allergic adverse reactions that can potentially occur after vaccination and individual vaccine components capable of causing the allergic adverse reactions. We present the incidence of allergic adverse reactions during clinical studies and through post-authorization and post-marketing surveillance and provide plausible causes of these reactions based on potential allergenic components present in several common vaccines. Additionally, we review implications for individual diagnosis and management and vaccine manufacturing overall. Finally, we suggest areas for future research.

Published
2021

37. COVID-19 pandemic:Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Author

Pfaar, Oliver, Klimek, Ludger, Jutel, Marek, Akdis, Cezmi A., Bousquet, Jean, Breiteneder, Heimo, Chinthrajah, Sharon, Diamant, Zuzana, Eiwegger, Thomas, Fokkens, Wytske J., Fritsch, Hans Walter, Nadeau, Kari C., O’Hehir, Robyn E., O’Mahony, Liam, Rief, Winfried, Sampath, Vanitha, Schedlowski, Manfred, Torres, María José, Traidl-Hoffmann, Claudia, Wang, De Yun, Zhang, Luo, Bonini, Matteo, Brehler, Randolf, Brough, Helen Annaruth, Chivato, Tomás, Del Giacco, Stefano R., Dramburg, Stephanie, Gawlik, Radoslaw, Gelincik, Aslı, Hoffmann-Sommergruber, Karin, Hox, Valerie, Knol, Edward F., Lauerma, Antti, Matricardi, Paolo M., Mortz, Charlotte G., Ollert, Markus, Palomares, Oscar, Riggioni, Carmen, Schwarze, Jürgen, Skypala, Isabel, Untersmayr, Eva, Walusiak-Skorupa, Jolanta, Ansotegui, Ignacio J., Bachert, Claus, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, Giorgio Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Cruz, Alvaro A., Czarlewski, Wienczyslawa, Fonseca, João A., Gotua, Maia, Haahtela, Tari, Ivancevich, Juan Carlos, Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Désirée Erlinda, Abdul Latiff, Amir Hamzah, Mäkelä, Mika, Morais-Almeida, Mário, Mullol, Joaquim, Naclerio, Robert, Ohta, Ken, Okamoto, Yoshitaka, Onorato, Gabrielle L., Papadopoulos, Nikolaos G., Patella, Vincenzo, Regateiro, Frederico S., Samoliński, Bolesław, Suppli Ulrik, Charlotte, Toppila-Salmi, Sanna, Valiulis, Arunas, Ventura, Maria Teresa, Yorgancioglu, Arzu, Zuberbier, Torsten, Agache, Ioana, Pfaar, Oliver, Klimek, Ludger, Jutel, Marek, Akdis, Cezmi A., Bousquet, Jean, Breiteneder, Heimo, Chinthrajah, Sharon, Diamant, Zuzana, Eiwegger, Thomas, Fokkens, Wytske J., Fritsch, Hans Walter, Nadeau, Kari C., O’Hehir, Robyn E., O’Mahony, Liam, Rief, Winfried, Sampath, Vanitha, Schedlowski, Manfred, Torres, María José, Traidl-Hoffmann, Claudia, Wang, De Yun, Zhang, Luo, Bonini, Matteo, Brehler, Randolf, Brough, Helen Annaruth, Chivato, Tomás, Del Giacco, Stefano R., Dramburg, Stephanie, Gawlik, Radoslaw, Gelincik, Aslı, Hoffmann-Sommergruber, Karin, Hox, Valerie, Knol, Edward F., Lauerma, Antti, Matricardi, Paolo M., Mortz, Charlotte G., Ollert, Markus, Palomares, Oscar, Riggioni, Carmen, Schwarze, Jürgen, Skypala, Isabel, Untersmayr, Eva, Walusiak-Skorupa, Jolanta, Ansotegui, Ignacio J., Bachert, Claus, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, Giorgio Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Cruz, Alvaro A., Czarlewski, Wienczyslawa, Fonseca, João A., Gotua, Maia, Haahtela, Tari, Ivancevich, Juan Carlos, Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Désirée Erlinda, Abdul Latiff, Amir Hamzah, Mäkelä, Mika, Morais-Almeida, Mário, Mullol, Joaquim, Naclerio, Robert, Ohta, Ken, Okamoto, Yoshitaka, Onorato, Gabrielle L., Papadopoulos, Nikolaos G., Patella, Vincenzo, Regateiro, Frederico S., Samoliński, Bolesław, Suppli Ulrik, Charlotte, Toppila-Salmi, Sanna, Valiulis, Arunas, Ventura, Maria Teresa, Yorgancioglu, Arzu, Zuberbier, Torsten, and Agache, Ioana

Abstract

Background: The coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics. Method: The scientific information on COVID-19 was analysed by a literature search in MEDLINE, PubMed, the National and International Guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library, and the internet. Results: Based on the diagnostic and treatment standards developed by EAACI, on international information regarding COVID-19, on guidelines of the World Health Organization (WHO) and other international organizations, and on previous experience, a panel of experts including clinicians, psychologists, IT experts, and basic scientists along with EAACI and the “Allergic Rhinitis and its Impact on Asthma (ARIA)” initiative have developed recommendations for the optimal management of allergy clinics during the current COVID-19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies. Conclusions: This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID-19 pandemic.

Published
2021

39. European Position Paper on Rhinosinusitis and Nasal Polyps 2020

Author

Fokkens, Wytske, Lund, Valerie, Hopkins, Claire, Hellings, Peter, Kern, Robert, Reitsma, Sietze, Toppila- Salmi, Sanna, Bernal-Sprekelsen, Manuel, Mullol, Joaquim, Alobid, Isam, Anselmo- Lima, Wilma Terezinha, Bachert, Claus, Baroody, Fuad, von Buchwald, Christian, Cervin, Anders, Cohen, Noam, Constantinidis, Jannis, De Gabory, Ludovic, Desrosiers, Martin, Diamant, Zuzana, Douglas, Richard, Gevaert, Philippe, Hafner, Anita, Harvey, Richard, Joos, Guy, Kalogjera, Livije, Knill, Andrew, Kocks, Janwillem, Landis, Basile, Limpens, Jacqueline, Lebeer, Sarah, Lourenco, Olga, Matricardi, Paolo, Meco, Cem, O’Mahony, Liam, Philpott, Carl, Ryan, Dermot, Schlosser, Rodney, Senior, Brent, Smith, Timothy, Teeling, Thijs, Tomazic, Peter Valentin, Wang, De Yun, Wang, Dehui, Zhang, Luo, Agius, Adrian, Ahlström-Emanuelsson, Cecilia, Alabri, Rashid, Albu, Silviu, Alhabash, Saied, Aleksic, Aleksandra, Aloulah, Mohammad, Al- Qudah, Mohannad, Alsaleh, Saad, Baban, Muaid Aziz, Baudoin, Tomislav, Balvers, Tijmen, Battaglia, Paolo, Bedoya, Juan David, Beule, Achim, Bofares, Khaled, Braverman, Itzhak, Brozek-Madry, Eliza, Byaruhanga, Richard, Callejas, Claudio, Carrie, Sean, Caulley, Lisa, Chussi, Desderius, de Corso, Eugenio, Coste, Andre, El Hadi, Usama, Elfarouk, Ahmed, Eloy, Philippe, Farrokhi, Shokrollah, Felisati, Giovanni, Ferrari, Michel, Fishchuk, Roman, Grayson, Jessica, Goncalves, Paulo, Grdinic, Boris, Grgic, Velimir, Hamizan, Aneeza, Heinichen, Julio, Husain, Salina, Ing Ping, Tang, Ivaska, Justinas, Jakimovska, Frodita, Jovancevic, Ljiljana, Kakande, Emily, Kamel, Reda, Karpischenko, Sergei, Kariyawasam, Harsha, Kawauchi, Hideyuki, Kjeldsen, Anette, Klimek, Ludger, Krzeski, Antoni, Kopacheva Barsova, Gabriela, Wam Kim, Sung, Lal, Devyani, Letort, José, Lopatin, Andrey, Mahdjoubi, Abdelhak, Mesbahi, Alireza, Netkovski, Jane, Nyenbue Tshipukane, Dieudonné, Obando-Valverde, Andrés, Okano, Mitsuhiro, Onerci111, Metin, Ong, Yew Kwang, Orlandi, Richard, Otori, Nobuyoshi, Ouennoughy, Kheir, Ozkan, Muge, Peric, Aleksandar, Plzak, Jan, Prokopakis, Emmanuel, Prepageran, Nerayanan, Psaltis, Alkis, Pugin, Benoit, Raftopulos, Marco, Rombaux, Philippe, Riechelmann, Herbert, Sahtout, Semia, Sarafoleanu, Caius-Codrut, Searyoh, Kafui, Rhee, Chae-Seo, Shi, Jianbo, Shkoukani, Mahdi, Shukuryan, Arthur, Sicak, Marian, Smyth, David, Snidvongs, Kornkiat, Soklic Kosak, Tanja, Stjärne, Pär, Sutikno, Budi, Steinsvåg, Sverre, Tantilipikorn, Pongsakorn, Thanaviratananich, Sanguansak, Tran, Thuy, Urbancic, Jure, Valiulis, Arunas, Vasquez de Aparicio, Carolina, Vicheva, Dilyana, Virkkula, Paula, Vicente, Gil, Voegels, Richard, Wagenmann, Martin, Wardani, Retno, Welge-Lussen, Antje, Witterick, Ian, Wright, Erin, Zabolotniy, Dmytro, Zsolt, Bella, Zwetsloot, Casper, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, Korva-, nenä- ja kurkkutautien klinikka, HUS Head and Neck Center, uBibliorum, Faculteit Medische Wetenschappen/UMCG, Fokkens, Wytske J., UCL - (MGD) Service d'oto-rhino-laryngologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'oto-rhino-laryngologie, Ear, Nose and Throat, and AII - Inflammatory diseases

Subjects
Adult, medicine.medical_specialty, Evidence-based practice, Rhinosinusitis, MEDLINE, Therapeutics, PLACEBO-CONTROLLED TRIAL, 03 medical and health sciences, 0302 clinical medicine, Nasal Polyps, QUALITY-OF-LIFE, Diagnosis, paranasal sinus diseases, nasal polyps, therapeutics, diagnosis, asthma, prevention, control, Paranasal Sinus Diseases, Humans, Medicine, Nasal polyps, ENDOSCOPIC-SINUS-SURGERY, 3125 Otorhinolaryngology, ophthalmology, Sinusitis, Prevention and Control, Child, 030223 otorhinolaryngology, Intensive care medicine, UPPER RESPIRATORY-TRACT, TERM-FOLLOW-UP, Rhinitis, Science & Technology, business.industry, General Medicine, Guideline, Evidence-based medicine, RANDOMIZED CONTROLLED-TRIAL, medicine.disease, ACUTE MAXILLARY SINUSITIS, Asthma, 3. Good health, Integrated care, CHURG-STRAUSS-SYNDROME, Otorhinolaryngology, Acute Disease, Chronic Disease, Position paper, PRIMARY CILIARY DYSKINESIA, Human medicine, business, ALLERGIC FUNGAL RHINOSINUSITIS, Life Sciences & Biomedicine
Abstract

The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively covered in EPOS2012 such as paediatric CRS and sinus surgery. EPOS2020 also involves new stakeholders, including pharmacists and patients, and addresses new target users who have become more involved in the management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using over the counter treatments. The document provides suggestions for future research in this area and offers updated guidance for definitions and outcome measurements in research in different settings. EPOS2020 contains chapters on definitions and classification where we have defined a large number of terms and indicated preferred terms. A new classification of CRS into primary and secondary CRS and further division into localized and diffuse disease, based on anatomic distribution is proposed. There are extensive chapters on epidemiology and predisposing factors, inflammatory mechanisms, (differential) diagnosis of facial pain, allergic rhinitis, genetics, cystic fibrosis, aspirin exacerbated respiratory disease, immunodeficiencies, allergic fungal rhinosinusitis and the relationship between upper and lower airways. The chapters on paediatric acute and chronic rhinosinusitis are totally rewritten. All available evidence for the management of acute rhinosinusitis and chronic rhinosinusitis with or without nasal polyps in adults and children is systematically reviewed and integrated care pathways based on the evidence are proposed. Despite considerable increases in the amount of quality publications in recent years, a large number of practical clinical questions remain. It was agreed that the best way to address these was to conduct a Delphi exercise . The results have been integrated into the respective sections. Last but not least, advice for patients and pharmacists and a new list of research needs are included. The full document can be downloaded for free on the website of this journal: http://www.rhinologyjournal.com. ispartof: RHINOLOGY vol:58 issue:Suppl S29 pages:I-+ ispartof: location:Netherlands status: published

Published
2020

40. Point-of-care biomarkers in asthma management : Time to move forward

Author

Alving, Kjell, Diamant, Zuzana, Lucas, Sarah, Magnussen, Helgo, Pavord, Ian D., Piacentini, Giorgio, Price, David, Roche, Nicolas, Sastre, Joaquin, Thomas, Mike, Usmani, Omar, Bjermer, Leif, Alving, Kjell, Diamant, Zuzana, Lucas, Sarah, Magnussen, Helgo, Pavord, Ian D., Piacentini, Giorgio, Price, David, Roche, Nicolas, Sastre, Joaquin, Thomas, Mike, Usmani, Omar, and Bjermer, Leif

Published
2020
Full Text
View/download PDF

41. Real-life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA.

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'oto-rhino-laryngologie, Seys, Sven F, De Bont, Shana, Fokkens, Wytske J, Bachert, Claus, Alobid, Isam, Bernal-Sprekelsen, Manuel, Bjermer, Leif, Callebaut, Ina, Cardell, Lars-Olaf, Carrie, Sean, Castelnuovo, Paolo, Cathcart, Russell, Constantinidis, Jannis, Cools, Leen, Cornet, Marjolein, Clement, Gregory, Cox, Tony, Delsupehe, Lieve, Correia-de-Sousa, Jaime, Deneyer, Lauren, De Vos, Geert, Diamant, Zuzana, Doulaptsi, Maria, Gane, Simon, Gevaert, Philippe, Hopkins, Claire, Hox, Valérie, Hummel, Thomas, Hosemann, Werner, Jacobs, Raf, Jorissen, Mark, Kjeldsen, Anette, Landis, Basile N, Lemmens, Winde, Leunig, Andreas, Lund, Valerie, Mariën, Gert, Mullol, Joaquim, Onerci, Metin, Palkonen, Susanna, Proano, Isabel, Prokopakis, Emmanuel, Ryan, Dermot, Riechelmann, Herbert, Sahlstrand-Johnson, Pernilla, Salmi-Toppila, Sanna, Segboer, Christine, Speleman, Kato, Steinsvik, Andreas, Surda, Pavol, Tomazic, Peter-Valentin, Vanderveken, Olivier, Van Gerven, Laura, Van Zele, Thibaut, Verfaillie, Jan, Verhaeghe, Benedicte, Vierstraete, Kathie, Vlaminck, Stephan, Wagenmann, Martin, Pugin, Benoit, Hellings, Peter W, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'oto-rhino-laryngologie, Seys, Sven F, De Bont, Shana, Fokkens, Wytske J, Bachert, Claus, Alobid, Isam, Bernal-Sprekelsen, Manuel, Bjermer, Leif, Callebaut, Ina, Cardell, Lars-Olaf, Carrie, Sean, Castelnuovo, Paolo, Cathcart, Russell, Constantinidis, Jannis, Cools, Leen, Cornet, Marjolein, Clement, Gregory, Cox, Tony, Delsupehe, Lieve, Correia-de-Sousa, Jaime, Deneyer, Lauren, De Vos, Geert, Diamant, Zuzana, Doulaptsi, Maria, Gane, Simon, Gevaert, Philippe, Hopkins, Claire, Hox, Valérie, Hummel, Thomas, Hosemann, Werner, Jacobs, Raf, Jorissen, Mark, Kjeldsen, Anette, Landis, Basile N, Lemmens, Winde, Leunig, Andreas, Lund, Valerie, Mariën, Gert, Mullol, Joaquim, Onerci, Metin, Palkonen, Susanna, Proano, Isabel, Prokopakis, Emmanuel, Ryan, Dermot, Riechelmann, Herbert, Sahlstrand-Johnson, Pernilla, Salmi-Toppila, Sanna, Segboer, Christine, Speleman, Kato, Steinsvik, Andreas, Surda, Pavol, Tomazic, Peter-Valentin, Vanderveken, Olivier, Van Gerven, Laura, Van Zele, Thibaut, Verfaillie, Jan, Verhaeghe, Benedicte, Vierstraete, Kathie, Vlaminck, Stephan, Wagenmann, Martin, Pugin, Benoit, and Hellings, Peter W

Abstract

BACKGROUND: Chronic rhinosinusitis (CRS) is a chronic inflammatory disease associated with a substantial personal and socioeconomic burden. Monitoring of patient-reported outcomes by mobile technology offers the possibility to better understand real-life burden of CRS. METHODS: This study reports on the cross-sectional evaluation of data of 626 users of mySinusitisCoach (mSC), a mobile application for CRS patients. Patient characteristics of mSC users were analysed as well as the level of disease control based on VAS global rhinosinusitis symptom score and adapted EPOS criteria. RESULTS: The mSC cohort represents a heterogeneous group of CRS patients with a diverse pattern of major symptoms. Approximately half of patients reported nasal polyps. 47.3% of all CRS patients were uncontrolled based on evaluation of VAS global rhinosinusitis symptom score compared to 40.9% based on adapted EPOS criteria. The impact of CRS on sleep quality and daily life activities was significantly higher in uncontrolled versus well-controlled patients. Half of patients had a history of FESS (functional endoscopic sinus surgery) and reported lower symptom severity compared to patients without a history of FESS, except for patients with a history of more than 3 procedures. Patients with a history of FESS reported higher VAS levels for impaired smell. CONCLUSION: Real-life data confirm the high disease burden in uncontrolled CRS patients, clearly impacting quality of life. Sinus surgery improves patient-reported outcomes, but not in patients with a history of more than 3 procedures. Mobile technology opens a new era of real-life monitoring, supporting the evolution of care towards precision medicine.

Published
2020

42. Precision medicine and treatable traits in chronic airway diseases - where do we stand?

Author

Ulrik, Charlotte Suppli, Vijverberg, Susanne, Hanania, Nicola A, Diamant, Zuzana, Ulrik, Charlotte Suppli, Vijverberg, Susanne, Hanania, Nicola A, and Diamant, Zuzana

Abstract

PURPOSE OF REVIEW: To provide an update on the implementation of precision medicine, based on treatable traits and mechanisms, in the daily clinical management of chronic airways diseases.RECENT FINDINGS: Recent insights into the complex and heterogeneous nature of chronic airway diseases including chronic obstructive pulmonary disease (COPD) and asthma identified several clinical and inflammatory phenotypes. This shifted the management focus of these diseases away from the prototypic disease labels and paved the way for developing novel targeted therapies.The concept of precision medicine aims to link the right patient to the right treatment, while minimizing the risk of adverse effects. Several treatable features ('treatable traits') have now been identified for these chronic airway diseases, including pulmonary, extra-pulmonary, and psychological/lifestyle/environmental traits. As the next step, innovative detection techniques should clarify underlying mechanisms and molecular pathways of these treatable traits and novel reliable point-of-care (composite) biomarkers to help predict responders to targeted therapies must be developed.SUMMARY: Precision medicine links the right patient to the right treatment. Identification of treatable traits in asthma and COPD will help optimize the treatment approach in these heterogeneous diseases. Furthermore, in-depth identification of underlying molecular pathways and reliable biomarkers in chronic airways diseases to guide targeted treatment in individual patients is in progress.

Published
2020

43. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Author

Breiteneder, Heimo; https://orcid.org/0000-0003-2022-8689, Peng, Ya-Qi; https://orcid.org/0000-0003-0084-9541, Agache, Ioana; https://orcid.org/0000-0001-7994-364X, Diamant, Zuzana; https://orcid.org/0000-0003-0133-0100, Eiwegger, Thomas; https://orcid.org/0000-0002-2914-7829, Fokkens, Wytske J; https://orcid.org/0000-0003-4852-229X, Traidl-Hoffmann, Claudia; https://orcid.org/0000-0001-5085-5179, Nadeau, Kari; https://orcid.org/0000-0002-2146-2955, O'Hehir, Robyn E; https://orcid.org/0000-0002-3489-7595, O'Mahony, Liam; https://orcid.org/0000-0003-4705-3583, Pfaar, Oliver; https://orcid.org/0000-0003-4374-9639, Torres, Maria J; https://orcid.org/0000-0001-5228-471X, Wang, De-Yun; https://orcid.org/0000-0002-0909-2963, Zhang, Luo; https://orcid.org/0000-0002-0910-9884, Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X, Breiteneder, Heimo; https://orcid.org/0000-0003-2022-8689, Peng, Ya-Qi; https://orcid.org/0000-0003-0084-9541, Agache, Ioana; https://orcid.org/0000-0001-7994-364X, Diamant, Zuzana; https://orcid.org/0000-0003-0133-0100, Eiwegger, Thomas; https://orcid.org/0000-0002-2914-7829, Fokkens, Wytske J; https://orcid.org/0000-0003-4852-229X, Traidl-Hoffmann, Claudia; https://orcid.org/0000-0001-5085-5179, Nadeau, Kari; https://orcid.org/0000-0002-2146-2955, O'Hehir, Robyn E; https://orcid.org/0000-0002-3489-7595, O'Mahony, Liam; https://orcid.org/0000-0003-4705-3583, Pfaar, Oliver; https://orcid.org/0000-0003-4374-9639, Torres, Maria J; https://orcid.org/0000-0001-5228-471X, Wang, De-Yun; https://orcid.org/0000-0002-0909-2963, Zhang, Luo; https://orcid.org/0000-0002-0910-9884, and Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X

Abstract

Modern health care requires a proactive and individualized response to diseases, combining precision diagnosis and personalized treatment. Accordingly, the approach to patients with allergic diseases encompasses novel developments in the area of personalized medicine, disease phenotyping and endotyping, and the development and application of reliable biomarkers. A detailed clinical history and physical examination followed by the detection of IgE immunoreactivity against specific allergens still represents the state of the art. However, nowadays, further emphasis focuses on the optimization of diagnostic and therapeutic standards and a large number of studies have been investigating the biomarkers of allergic diseases, including asthma, atopic dermatitis, allergic rhinitis, food allergy, urticaria and anaphylaxis. Various biomarkers have been developed by omics technologies, some of which lead to a better classification of distinct phenotypes or endotypes. The introduction of biologicals to clinical practice increases the need for biomarkers for patient selection, prediction of outcomes and monitoring, to allow for an adequate choice of the duration of these costly and long-lasting therapies. Escalating healthcare costs together with questions about the efficacy of the current management of allergic diseases require further development of a biomarker-driven approach. Here, we review biomarkers in diagnosis and treatment of asthma, atopic dermatitis, allergic rhinitis, viral infections, chronic rhinosinusitis, food allergy, drug hypersensitivity and allergen immunotherapy with a special emphasis on specific IgE, the microbiome and the epithelial barrier. In addition, EAACI guidelines on biologicals are discussed within the perspective of biomarkers.

Published
2020

45. Activated CD8+CD38+ Cells Are Associated With Worse Clinical Outcome in Hospitalized COVID-19 Patients.

Author

Bobcakova, Anna, Barnova, Martina, Vysehradsky, Robert, Petriskova, Jela, Kocan, Ivan, Diamant, Zuzana, and Jesenak, Milos

Subjects
SARS-CoV-2, COVID-19, BLOOD cell count, KILLER cells, HOSPITAL patients, HISTOCOMPATIBILITY antigens
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that spread around the world during the past 2 years, has infected more than 260 million people worldwide and has imposed an important burden on the healthcare system. Several risk factors associated with unfavorable outcome were identified, including elderly age, selected comorbidities, immune suppression as well as laboratory markers. The role of immune system in the pathophysiology of SARS-CoV-2 infection is indisputable: while an appropriate function of the immune system is important for a rapid clearance of the virus, progression to the severe and critical phases of the disease is related to an exaggerated immune response associated with a cytokine storm. We analyzed differences and longitudinal changes in selected immune parameters in 823 adult COVID-19 patients hospitalized in the Martin University Hospital, Martin, Slovakia. Examined parameters included the differential blood cell counts, various parameters of cellular and humoral immunity (serum concentration of immunoglobulins, C4 and C3), lymphocyte subsets (CD3+, CD4+, CD8+, CD19+, NK cells, CD4+CD45RO+), expression of activation (HLA-DR, CD38) and inhibition markers (CD159/NKG2A). Besides already known changes in the differential blood cell counts and basic lymphocyte subsets, we found significantly higher proportion of CD8+CD38+ cells and significantly lower proportion of CD8+NKG2A+ and NK NKG2A+ cells on admission in non-survivors, compared to survivors; recovery in survivors was associated with a significant increase in the expression of HLA-DR and with a significant decrease of the proportion of CD8+CD38+cells. Furthermore, patients with fatal outcome had significantly lower concentrations of C3 and IgM on admission. However, none of the examined parameters had sufficient sensitivity or specificity to be considered a biomarker of fatal outcome. Understanding the dynamic changes in immune profile of COVID-19 patients may help us to better understand the pathophysiology of the disease, potentially improve management of hospitalized patients and enable proper timing and selection of immunomodulator drugs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Prevalence and Characteristics of Asthma-COPD Overlap in Routine Primary Care Practices

Author

Krishnan, Jerry A, Nibber, Anjan, Chisholm, Alison, Price, David, Bateman, Eric D, Bjermer, Leif, van Boven, Job Fm, Brusselle, Guy, Costello, Richard W, Dandurand, Ronald J, Diamant, Zuzana, Van Ganse, Eric, Gouder, Caroline, van Kampen, Sanne C, Kaplan, Alan, Kocks, Janwillem, Miravitlles, Marc, Niimi, Akio, Pizzichini, Emilio, Rhee, Chin Kook, Soriano, Joan B, Vogelmeier, Claus, Román-Rodriguez, Miguel, Carter, Victoria, Roche, Nicolas, Value, Affordability and Sustainability (VALUE), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), and Groningen Research Institute for Asthma and COPD (GRIAC)

Subjects
EPIDEMIOLOGY, RESPIRATORY HEALTH, copd, asthma, respiratory tract diseases, PREVALENCE
Abstract

RATIONALE: Adults may exhibit characteristics of both asthma and chronic obstructive pulmonary disease (COPD), a situation recently described as asthma-COPD overlap (ACO). There is a paucity of information about ACO in primary care. OBJECTIVES: 1) Estimate the prevalence and describe characteristics of individuals with ACO in primary care practices among patients currently diagnosed with asthma, COPD, or both; and 2) Compare the prevalence and characteristics of ACO between the three source populations. METHODS: The Respiratory Effectiveness Group (REG) conducted a cross-sectional study of individuals ≥40 years old and with ≥2 outpatient primary care visits over a 2-year period in the United Kingdom's Optimum Patient Care Research Database (OPCRD). Patients were classified into one of three source populations based on diagnostic codes: (A) COPD only; (B) both asthma and COPD; or (C) asthma only. ACO was defined as the presence of all of the following: (1) age ≥40 years; (2) current or former smoking, (3) post-bronchodilator (BD) airflow limitation (forced expired volume in the first second [FEV1] / forced vital capacity [FVC] < 0.7), and (4) ≥12% and ≥200 mL reversibility in post-BD FEV1. RESULTS: Among 2,165 individuals (1,015 COPD only, 395 with both asthma and COPD, and 755 asthma only), the overall prevalence of ACO was 20% (95% CI 18 to 23%). Patients with ACO had a mean age of 70 years (standard deviation 11 years), 60% were men, 73% were former smokers (rest were current smokers), and 66% were overweight or obese. Comorbid conditions were common in patients with ACO, including diabetes (53%), cardiovascular disease (36%), hypertension (30%), eczema (23%), and rhinitis (21%). The prevalence of ACO was higher in patients with a diagnosis of both asthma and COPD (32%) compared with a diagnosis of COPD only (20%, p

Published
2019

49. Европейский стратегический форум по аллергическим болезням : определение приоритетов научных проблем и финансирования в отношении аллергии и бронхиальной астмы и необходимость трансляционных исследований

Author

Agache, Ioana, Annesi-Maesano, Isabella, Bonertz, Andreas, Branca, Francesco, Cant, Andrew, Fras, Zlatko, Ingenrieth, Frank, Namazova-Baranova, Leyla, Odemyr, Mikaela, Spanevello, Antonio, Vieths, Stefan, Yorgancioglu, Arzu, Alvaro-Lozano, Montserat, Hernandez, Domingo Barber, Chivato, Tomas, Del Giacco, Stefano, Diamant, Zuzana, Eguiluz-Gracia, Ibon, van Wijk, Roy Gert, Gevaert, Philippe, Graessel, Anke, Hellings, Peter, Hoffmann-Sommergruber, Karin, Jutel, Marek, Lau, Susanne, Lauerma, Antti, Olaguibel, Jose Maria, O'Mahony, Liam, Ozdemir, Cevdet, Palomares, Oscar, Pfaar, Oliver, Sastre, Joaquin, Scadding, Glennis, Schmidt-Weber, Carsten, Schmid-Grendelmeier, Peter, Shamji, Mohamed, Skypala, Isabel, Spinola, Monica, Spranger, Otto, Torres, Maria, Vereda, Andrea, Bonini, Sergio, Helsingfors universitet, Kliniken för hud- och könssjukdomar, Universitetets ledning, and HUS Inflammationscentrum

Subjects
3121 General medicine, internal medicine and other clinical medicine
Abstract

The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients' organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results